Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av Amivantamab subkutan (SC) administrering för behandling av avancerade solida maligniteter (PALOMA)

2 november 2026 uppdaterad av: Janssen Research & Development, LLC

En öppen, multicenter, dosupptrappning fas 1b-studie för att utvärdera säkerheten och farmakokinetiken för subkutan tillförsel av Amivantamab, en human bispecifik EGFR- och cMet-antikropp för behandling av avancerade fasta maligniteter

The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Studietyp

Interventionell

Inskrivning (Faktisk)

158

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • West Hollywood, California, Förenta staterna, 90048
        • Cedars Sinai Medical Center
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46256
        • Community Health Network
    • New York
      • New York, New York, Förenta staterna, 10016
        • Langone Health at NYC University, NYU School of Medicine
    • Oregon
      • Portland, Oregon, Förenta staterna, 97213
        • Providence Portland Medical Center
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Sarah Cannon Research Institute
    • Ontario
      • Toronto, Ontario, Kanada, M5G 2M9
        • University Health Network
      • Manchester, Storbritannien, M20 4BX
        • The Christie Nhs Foundation Trust
      • Sutton, Storbritannien, SM2 5PT
        • Royal Marsden Hospital
      • Cheongju-si, Sydkorea, 28644
        • Chungbuk National University Hospital
      • Seongnam-si, Sydkorea, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Sydkorea, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Sydkorea, 06351
        • Samsung Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria:

  • Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records.
  • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug
  • A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])

Exclusion criteria:

  • Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded
  • Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels
  • Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible
  • Participant has an active malignancy other than the disease under study requiring treatment
  • Participant has leptomeningeal disease

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part 1: Ami-LC-MD and Ami-LC

Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.

Participants will receive amivantamab admixed with rHuPH20 SC infusion.

Participants will receive amivantamab SC infusion.

Experimentell: Part 2: Ami-HC and Ami-HC-CF

Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or SC injection of amivantamab co-formulated with rHuPH20 (Ami-HC-CF).

Participants will receive amivantamab SC infusion.

Participants will receive amivantamab co-formulated with rHuPH20 as SC injection.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
Tidsram: Up to Day 29

Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration.

Up to Day 29
Number of Participants with Adverse Event (AE)
Tidsram: Up to 4 years 1 month

An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Up to 4 years 1 month
Number of Participants with Dose Limiting Toxicity (DLT)
Tidsram: Up to Day 28

Number of participants with DLT will be assessed.

Up to Day 28
Number of Participants with Clinical Laboratory Abnormalities
Tidsram: Up to 4 years 1 month

Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed.

Up to 4 years 1 month

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies
Tidsram: Up to 4 years 1 month

Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed.

Up to 4 years 1 month
Epidermal Growth Factor Receptor (EGFR) Concentrations
Tidsram: Up to 4 years 1 month

EGRF concentrations markers will be assessed.

Up to 4 years 1 month
Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers
Tidsram: Up to 4 years 1 month

cMET markers will be analyzed.

Up to 4 years 1 month
Overall Response Rate (ORR)
Tidsram: Up to 4 years 1 month

ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1.

Up to 4 years 1 month
Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State
Tidsram: Up to 4 years 1 month

Maximum amivantamab dosing interval Between time zero to steady state will be assessed.

Up to 4 years 1 month

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 november 2020

Primärt slutförande (Faktisk)

11 juli 2024

Avslutad studie (Beräknad)

1 april 2027

Studieregistreringsdatum

Först inskickad

6 oktober 2020

Först inskickad som uppfyllde QC-kriterierna

22 oktober 2020

Första postat (Faktisk)

28 oktober 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CR108891
  • 2020-003225-36 (EudraCT-nummer)
  • 61186372NSC1003 (Annan identifierare: Janssen Research & Development, LLC)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera